Background: One well-known hormonal disease, polycystic ovarian syndrome (PCOS), is linked to an elevated risk
of periodontal inflammation. Whether or not (PCOS) is present, periodontitis, a chronic inflammatory illness of the
gums.
Aim of study: Comparing salivary levels of neutrophil elastatse (NE) in healthy controls and patients with
polycystic ovarian syndrome who have periodontitis is the primary goal of this investigation.
Methodology: From January to July, 2022, the study was conducted. There were 85 participants in the current
study, ranging in age from (20-40) years. The participants in this study were divided into four groups: those without
periodontitis (n=10), those with periodontitis and (PCOS) (n=25), and those with both conditions (n=25).
Results: Periodontitis group had the highest median plaque index (PI), followed by mixed group, PCOS group, and
finally groupings (p< 0.001). Compared to the periodontitis and combination groups, the control and PCOS groups
exhibited considerably decreased bleeding on probing median level (p<0.001). However, compared to the
periodontitis and mixed groups, the PCOS group had a much lower level (p<0.001). In contrast to combined group,
the periodontitis group had a considerably lower median level of PPD (p<0.001). The median levels of NE were
found to be dropping in the following order: periodontitis, control, mixed, and PCOS groups, according to Intragroup comparison.
Conclusion: Those with polycystic ovary syndrome (PCOS) are more likely to experience periodontal inflammation
and tissue damage than those without PCOS. Reducing neutrophil elastase production is one mechanism by which
anti-inflammatory drugs may alleviate periodontal inflammation
Hi! I can explain how to publish or share, find articles in your field, format citations and answer questions about fees and licensing. How can I help?
Answers are based on The Gufo’s published policies. Editorial decisions are made by the editorial team.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
